Recommended dosage

  • The recommended dosage of ROLVEDON™ is a single subcutaneous injection of 13.2 mg administered once per chemotherapy cycle
  • Administer approximately 24 hours after cytotoxic chemotherapy
  • Do not administer within the period from 14 days before to 24 hours after administration of cytotoxic chemotherapy
  • Based on the molecular mass of components, a 13.2 mg dose of eflapegrastim‑xnst contains 9.6 mg Fc, 0.66 mg flexible polyethylene glycol (PEG) linker, and 3.6 mg G-CSF


  1. Refridgerator

    Remove ROLVEDON from the refrigerator

  2. Timer

    Keep the prefilled syringe inside the carton for a minimum of 30 minutes

  3. Syringe

    Administer ROLVEDON subcutaneously via a single-dose

  • Trash

    Discard any prefilled syringe left at room temperature for longer than 12 hours

  • Shake

    Do not shake

  • Freeze/cold

    If ROLVEDON is accidentally frozen, do not use

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Do not administer ROLVEDON if discoloration or particulates are observed.

Administer the entire contents of the prefilled syringe.


  1. ROLVEDON [package insert]. Irvine, CA: Spectrum Pharmaceuticals, Inc.

Access4Me™ provides access and reimbursement support for your patients